Currently out of the existing stock ratings of Joel Beatty, 65 are a HOLD (16.54%), 7 are a SELL (1.78%), 321 are a BUY (81.68%).

Joel Beatty

Work Performance Price Targets & Ratings Chart

Analyst Joel Beatty, currently employed at BAIRD, carries an average stock price target met ratio of 61.71% that have a potential upside of 46.56% achieved within 327 days.

Joel Beatty’s has documented 751 price targets and ratings displayed on 79 stocks. The coverage is on Healthcare, Consumer Defensive, Energy, Industrials sectors.

Most recent stock forecast was given on LRMR, Larimar Therapeutics at 30-Jun-2026.

Wall Street Analyst Joel Beatty

Analyst best performing recommendations are on NK (NANTKWEST).
The best stock recommendation documented was for AMAM (AMBRX BIOPHARMA AMERICAN DEPOSITARY SHARES) at 3/3/2023. The price target of $11 was fulfilled within 3 days with a profit of $4.57 (71.07%) receiving and performance score of 236.91.

Average potential price target upside

of $338.17 (36.83%) on FGEN (FIBROGEN).
of $93.03 (42.08%) on AMRN (AMARIN PLC).
of $79.15 (78.67%) on MLND (MILLENDO THERAPEUTICS).

ALNY Alnylam Pharmaceuticals AMRN Amarin PLC ARCT Arcturus Therapeutics Holdings ARNA Arena Pharmaceuticals BPMC Blueprint Medicines Corp CBAY Cymabay Therapeu DBVT DBV Technologies EIDX Eidos Therapeutics ESPR Esperion Therapeutics FGEN FibroGen HALO Halozyme Therapeutics IGMS IGM Biosciences IONS Ionis Pharmaceuticals MDCO The Medicines Company MDGL Madrigal Pharmaceuticals MIRM Mirum Pharmaceuticals NGM NGM Biopharmaceuticals NK NantKwest NVAX Novavax PHAS PhaseBio Pharmaceuticals PTCT PTC Therapeutics SLDB Solid Biosciences LLC SNDX Syndax Pharmaceuticals SRPT Sarepta Therapeutics VIR Vir Biotechnology VNDA Vanda Pharmaceuticals ARGX argenx NV ADR ARWR Arrowhead Pharmaceuticals CATB Catabasis Pharmaceuticals CRDF Cardiff Oncology EDIT Editas Medicine ICPT Intercept Pharmaceuticals NRIX Nurix Therapeutics BCEL Atreca TCON TRACON Pharmaceuticals GERN Geron KURA Kura Oncology NERV Minerva Neurosciences AMAM Ambrx Biopharma American Depositary Shares XFOR X4 Pharmaceuticals IDYA Ideaya Biosciences ATXS Astria Therapeutics BYSI BeyondSpring CDTX Cidara Therapeutics ELOX Eloxx Pharmaceuticals INO Inovio Pharmaceuticals LIFE aTyr Pharma MLND Millendo Therapeutics PLRX Pliant Therapeutics RARE Ultragenyx BMRN Biomarin Pharmaceutical LPTX Leap Therapeutics IBRX Immunitybio IMMP Immutep Ltd ADR COGT Cogent Biosciences ACAD ACADIA Pharmaceuticals SAGE Sage Therapeutic LBPH Longboard Pharmaceuticals AMLX Amylyx Pharmaceuticals AXSM Axsome Therapeutics ELF ELF Beauty JAZZ Jazz Pharmaceuticals PLC LRMR Larimar Therapeutics NGNE Neurogene CLDI Calidi Biotherapeutics ALKS Alkermes Plc CPRX Catalyst Pharmaceuticals DNLI Denali Therapeutics MNMD Mind Medicine CFLT Confluent PRAX Praxis Precision Medicines AM Antero Midstream Partners LP BCE BCE CAT Caterpillar CTNM Contineum Therapeutics, Common Stock DNTH Dianthus Therapeutics FG F&G Annuities & Life ITCI Intracellular Th MD Mednax

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Michael Ulz (MORGAN STANLEY)